1. OP0075 Impact of Different Infliximab Dose Regimens on Treatment Response and Drug Survival in 462 Patients with PSA. Results from the Nationwide Registries Danbio and Icebio. (10th June 2014) Authors: Glintborg, B.; Gudbjornsson, B.; Krogh, N.S.; Omerovic, E.; Manilo, N.; Holland-Fischer, M.; Lindegaard, H.; Loft, A.G.; Nordin, H.; Johnsen, L.; Oeftiger, S.F.; Hansen, A.; Rasmussen, C.; Grondal, G.; Geirsson, A.J.; Hetland, M.L. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0189 One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2, 061 patients with inflammatory arthritis followed in the danbio registry. (12th June 2018) Authors: Glintborg, B.; Sørensen, I.J.; Omerovic, E.; Mehnert, F.; Manilo, N.; Danebod, K.; Jensen, D.V.; Nordin, H.; Loft, A.G.; Hendricks, O.; Chrysidis, S.; Andersen, B.L.; Raun, J.L.; Lindegaard, H.; Espesen, J.; Jakobsen, S.H.; Hansen, I.M.J.; Dalsgaard, E.B.; Pedersen, D.D.; Kristensen, S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0038 Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in remission in routine care – 2-year outcomes and identification of predictors. (12th June 2018) Authors: Brahe, C.H.; Krabbe, S.; Østergaard, M.; Ørnbjerg, L.; Glinatsi, D.; Røgind, H.; Jensen, H.S.; Hansen, A.; Nørregaard, J.; Jacobsen, S.; Terslev, L.; Huynh, T.K.; Jensen, D.V.; Manilo, N.; Asmussen, K.; Frandsen, P.B.; Boesen, M.; Rastiemadabadi, Z.; Carlsen, L.M.; Møller, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0103 One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study. (12th June 2018) Authors: Glintborg, B.; Sørensen, I.J.; Omerovic, E.; Mehnert, F.; Manilo, N.; Danebod, K.; Jensen, D.V.; Nordin, H.; Loft, A.G.; Hendricks, O.; Chrysidis, S.; Andersen, B.L.; Raun, J.L.; Lindegaard, H.; Espesen, J.; Jakobsen, S.H.; Hansen, I.M.J.; Dalsgaard, E.B.; Pedersen, D.D.; Kristensen, S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB0263 Agreement between Das28, Acr/eular, Sdai, Cdai and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care. (15th July 2016) Authors: Brahe, C.H.; Terslev, L.; Krabbe, S.; Østergaard, M.; Røgind, H.; Jensen, H.S.; Hansen, A.; Nørregaard, J.; Jacobsen, S.; Ellegaard, K.; Fana, V.; Juul, L.; Huynh, T.; Jensen, D.; Manilo, N.; Asmussen, K.; Frandsen, P.B.; Pedersen, S.T.; Krogh, N.S.; Hetland, M.L. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 989 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0168 Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the danish nationwide danbio registry. (23rd January 2014) Authors: Glintborg, B.; Østergaard, M.; Krogh, N.; Tarp, U.; Loft, A.; Hansen, A.; Schlemmer, A.; Fana, V.; Kristensen, M.; Lindegaard, H.; Nordin, H.; Rasmussen, C.; Ejstrup, L.; Petersen, P.M.; Manilo, N.; Jensen, D.V.; Hetland, M.L. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0225 Three Months' Clinical Outcomes from A Nationwide Non-Medical Switch from Originator To Biosimilar Infliximab in Patients with Inflammatory Arthritis. Results from The Danbio Registry. (15th July 2016) Authors: Glintborg, B.; Juul Sørensen, I.; Vendelbo Jensen, D.; Krogh, N.S.; Loft, A.G.; Colic, A.; Espesen, J.; Olsen, J.; Hendricks, O.; Grydehøj, J.; Hansen, I.M.J.; Sørensen, M.V.; Chrysidis, S.; Manilo, N.; Klarlund, M.; Andersen, L.S.; Nordin, H.; Kristensen, S.; Hetland, M.L. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗